Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model

Phase I study of lentiviral-transduced chimeric antigen receptor modified T cells recognizing mesothelin in advanced solid cancers

(2019) Andrew R. Haas et al.   MOLECULAR THERAPY

Solid Tumors Challenges and New Insights of CAR T Cell Engineering

(2019) Safa Tahmasebi et al.   Stem Cell Reviews and Reports

CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

(2019) Linchun Jin et al.   Nature Communications

Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients

(2019) Takumi Kishimoto et al.   BMC CANCER

Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products

(2018) Kenneth Cornetta et al.   MOLECULAR THERAPY

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

(2018) Joseph A. Fraietta et al.   NATURE

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

(2018) Baohui Han et al.   JAMA Oncology

Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for non-small cell lung cancer therapy

(2018) Jun Lu et al.   EUROPEAN RESPIRATORY JOURNAL

DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells

(2018) Ruocong Zhao et al.   OncoImmunology

The Inflammatory CXC Chemokines, GROαhigh, IP-10low, and MIGlow, in Tumor Microenvironment Can Be Used as New Indicators for Non-small Cell Lung Cancer Progression

(2017) Ya Cao et al.   IMMUNOLOGICAL INVESTIGATIONS

Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells

(2017) Xiaoqing He et al.   Molecular Cancer

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy

(2016) Mark O'Hara et al.   Immunotherapy

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

(2016) Leonid Cherkassky et al.   JOURNAL OF CLINICAL INVESTIGATION

Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell–Treated Mice

(2016) Marie-Louise Sentman et al.   JOURNAL OF IMMUNOLOGY

Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors

(2016) Bing-Lan Zhang et al.   Science China-Life Sciences

Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer

(2016) Kaichao Feng et al.   Science China-Life Sciences

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases

(2015) S. C. Katz et al.   CLINICAL CANCER RESEARCH

Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors

(2015) Hinrich Abken   Immunotherapy

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

(2015) Nabil Ahmed et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen

(2014) Raffit Hassan et al.   CANCER

Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy

(2014) I. Pastan et al.   CANCER RESEARCH

Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma

(2013) S. S. Kachala et al.   CLINICAL CANCER RESEARCH

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

(2013) R. Hassan et al.   Science Translational Medicine

Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

(2013) G. L. Beatty et al.   Cancer Immunology Research

T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

(2013) M. V. Maus et al.   Cancer Immunology Research

Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

(2011) E. K. Moon et al.   CLINICAL CANCER RESEARCH

Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor

(2011) Evripidis Lanitis et al.   MOLECULAR THERAPY

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

(2011) Bin-Zhi Qian et al.   NATURE

Monocyte Chemoattractant Protein–1 Blockade Inhibits Lung Cancer Tumor Growth by Altering Macrophage Phenotype and Activating CD8+Cells

(2010) Zvi G. Fridlender et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor

(2010) Y. Zhao et al.   CANCER RESEARCH

Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers

(2010) R. Hassan et al.   CLINICAL CANCER RESEARCH

Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

(2010) John A. Craddock et al.   JOURNAL OF IMMUNOTHERAPY

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model

(2009) A. Di Stasi et al.   BLOOD